119th Congress

H.R. 3789

DTC Act of 2025

Introduced
In committee
Passed House
Passed Senate
To President
Became law

Sponsor: David J. Taylor(R-OH)
Introduced: Jun 5, 2025
Policy area: Health
Committees: House Committee on Energy and Commerce; House Committee on Ways and Means
Official text: Introduced in House · Congress.gov page

Cosponsors (8)

Original cosponsors (1)

Janice D. Schakowsky (D-IL)

Added later (7)

Mike Quigley (D-IL) · Jul 2, 2025
Nicholas J. Begich III (R-AK) · Jul 2, 2025
Eleanor Holmes Norton (D-DC) · Sep 30, 2025
Robert P. Bresnahan, Jr. (R-PA) · Sep 30, 2025
Zachary Nunn (R-IA) · Oct 3, 2025
Eugene Simon Vindman (D-VA) · Oct 21, 2025
Ashley Hinson (R-IA) · Jan 13, 2026

Summary

Summary by the Congressional Research Service· describes the “Introduced in House” version

Drug-price Transparency for Consumers Act of 2025 or the DTC Act of 2025 This bill requires consumer advertisements for prescription drugs and biological products to include certain price information if the drug or biologic is (1) covered under Medicare or Medicaid, and (2) required to include a risk summary under current law. Specifically, such advertisements must clearly and conspicuously disclose the wholesale price for a 30-day supply of the drug or biologic and may explain that a consumer may pay a different amount for the drug or biologic depending on the consumer's health insurance coverage. The requirement does not apply to advertisements for drugs or biologics with a wholesale cost of less than $35 for a one-month supply. Each violation of this requirement is subject to a civil penalty of not more than $100,000.

Roll-call votes

No recorded votes on this bill.

Actions

Jun 5, 2025 · House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jun 5, 2025
Introduced in House